Full Press Release Details
BridgeBio Pharma Expands Its Research Into Neuromuscular Disease To Include Limb-girdle Muscular Dystrophy Type 2 (LGMD2I) With New Subsidiary ML Bio Solutions.
BBIO
BridgeBio Pharma Expands Its Research Into Neuromuscular Disease To Include Limb-girdle Muscular Dystrophy Type 2 (LGMD2I) With New Subsidiary ML Bio Solutions
Key Takeaway: BridgeBio Pharma Expands Its Research Into Neuromuscular Disease To Include Limb-girdle Muscular Dystrophy Type 2 (LGMD2I) With New Subsidiary ML Bio Solutions